HDAC/JAK/BRD4-IN-1

HDAC/JAK/BRD4-IN-1

• CAS Number: 2755325-84-7
• UNSPSC Description: HDAC/JAK/BRD4-IN-1(compound 25ap) is a potent HDAC/JAK/BRD4 triple inhibitor. HDAC/JAK/BRD4-IN-1 inhibit cell growth and induces apoptosis in MDA-MB-231 cells, and shows anticancer activity in vivo[1].
• Target Antigen: Apoptosis; Epigenetic Reader Domain; HDAC; JAK
• Type: Reference compound
• Related Pathways: Apoptosis;Cell Cycle/DNA Damage;Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/hdac-jak-brd4-in-1.html
• Solubility: DMSO : 100 mg/mL (ultrasonic;warming;heat to 80°C)
• Smiles: ONC(C1=CC=C(C=C1)NC2=NC(NC3=CC=C(OCCN4CCCC4)C=C3)=NC=C2C)=O
• Molecular Weight: 448.52
• References & Citations: [1]Zhao C, et al. Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer [published online ahead of print, 2023 Oct 5]. J Med Chem. 2023;10.1021/acs.jmedchem.3c01242.
• Shipping Conditions: Room Temperature
• Clinical Information: No Development Reported